{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:11:23Z","timestamp":1786396283736,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["faseb.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The FASEB Journal"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diabetic nephropathy (DN) is a leading cause of end\u2010stage renal disease (ESRD). Hypertension increases kidney stress, which deteriorates function, and leads to peripheral renal vascular resistance. Long\u2010term hypoperfusion promotes interstitial fibrosis and glomerular sclerosis, resulting in nephrosclerosis. Although hypertension and DN are frequent ESRD complications, relevant animal models remain unavailable. We generated a deoxycorticosterone acetate (DOCA)\u2010salt hypertensive uni\u2010nephrectomized (UNx) KKA\n                    <jats:sup>y<\/jats:sup>\n                    mouse model demonstrating hypertension, hyperglycemia, cardiac hypertrophy, kidney failure, increased urinary albumin creatinine ratio (UACR), and increased renal PDE4D and cardiac PDE5A mRNA levels. We hypothesized that the novel PDE4 selective inhibitor, compound A, and PDE5 inhibitor, sildenafil, exhibit nephroprotective, and cardioprotective effects in this new model. Compound A, sildenafil, and the angiotensin II receptor blocker, irbesartan, significantly reduced ventricular hypertrophy and pleural effusion volume. Meanwhile, compound A and sildenafil significantly suppressed the UACR, urinary kidney injury molecule\u20101, and monocyte chemoattractant protein\u20101 levels, as well as that of renal pro\u2010fibrotic marker mRNAs, including collagen 1A1, fibronectin, and transforming growth factor\u2010beta (TGF\u2010\u03b2). Moreover, compound A significantly suppressed TGF\u2010\u03b2\u2010induced pro\u2010fibrotic mRNA expression in vitro in all major kidney lesions, including within the glomerular mesangial region, podocytes, and epithelial region. Hence, PDE4 and PDE5 inhibitors may be promising treatments, in combination with irbesartan, for DN with hypertension as they demonstrate complementary mechanisms.\n                  <\/jats:p>","DOI":"10.1096\/fj.202001084r","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:41:42Z","timestamp":1600306902000},"page":"14997-15014","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate\u2010salt hypertensive uni\u2010nephrectomized KKA\n                    <sup>y<\/sup>\n                    mice"],"prefix":"10.1096","volume":"34","author":[{"given":"Yasunori","family":"Nio","sequence":"first","affiliation":[{"name":"Extra\u2010Value Generation and General Medicine DDU Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugi","family":"Ookawara","sequence":"additional","affiliation":[{"name":"Extra\u2010Value Generation and General Medicine DDU Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Extra\u2010Value Generation and General Medicine DDU Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Tohyama","sequence":"additional","affiliation":[{"name":"Drug Metabolism &amp; Pharmacokinetics Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachio","family":"Shibata","sequence":"additional","affiliation":[{"name":"Drug Metabolism &amp; Pharmacokinetics Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sano","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Anayama","sequence":"additional","affiliation":[{"name":"Drug Safety Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Hazama","sequence":"additional","affiliation":[{"name":"Extra\u2010Value Generation and General Medicine DDU Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Extra\u2010Value Generation and General Medicine DDU Takeda Pharmaceutical Company Limited Fujisawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2014.979151"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.55"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010080793"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.149"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.892580"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015101125"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1053"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01847.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.12.001"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00508.2007"},{"key":"e_1_2_10_12_1","first-page":"147","article-title":"Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD","volume":"4","author":"Giembycz MA","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2632-z"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2886"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00477.2019"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00669.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.03.018"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs391"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.711"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00098.x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10125-3"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44584"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2017.1419267"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111535"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000182"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep28715"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13753"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.04.024"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvy252"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00137.2018"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159872"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.287"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.3.974"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms16022320"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0022-3565(24)38895-0","article-title":"A novel phosphodiesterase type 4 inhibitor, YM976 (4\u2010(3\u2010chlorophenyl)\u20101,7\u2010diethylpyrido[2,3\u2010d] pyrimidin\u20102(1H)\u2010one), with little emetogenic activity","volume":"295","author":"Aoki M","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.01.021"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00669.x"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000343414"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90609.2008"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1159\/000158635"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1210\/me.2011-1009"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700249R"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2019.7868"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12459"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M802187200"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.04.003"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.01.017"}],"container-title":["The FASEB Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fj.202001084R","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1096\/fj.202001084R","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fj.202001084R","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:54:11Z","timestamp":1761695651000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fj.202001084R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1096\/fj.202001084R"],"URL":"https:\/\/doi.org\/10.1096\/fj.202001084r","archive":["Portico"],"relation":{},"ISSN":["0892-6638","1530-6860"],"issn-type":[{"value":"0892-6638","type":"print"},{"value":"1530-6860","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,16]]},"assertion":[{"value":"2020-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}